Q3 EPS Estimate for Indaptus Therapeutics Cut by Analyst

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for shares of Indaptus Therapeutics in a research note issued to investors on Wednesday, October 16th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.47) for the quarter, down from their previous forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.72) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($1.79) EPS, Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.38) EPS.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07.

Indaptus Therapeutics Stock Down 2.6 %

INDP opened at $1.51 on Monday. The stock has a fifty day moving average of $1.44 and a 200-day moving average of $1.98. The firm has a market capitalization of $12.89 million, a P/E ratio of -0.85 and a beta of 1.46. Indaptus Therapeutics has a 12-month low of $1.03 and a 12-month high of $3.25.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.17% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is currently owned by institutional investors and hedge funds.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.